JP2022515318A5 - - Google Patents

Info

Publication number
JP2022515318A5
JP2022515318A5 JP2021528872A JP2021528872A JP2022515318A5 JP 2022515318 A5 JP2022515318 A5 JP 2022515318A5 JP 2021528872 A JP2021528872 A JP 2021528872A JP 2021528872 A JP2021528872 A JP 2021528872A JP 2022515318 A5 JP2022515318 A5 JP 2022515318A5
Authority
JP
Japan
Prior art keywords
seq
sequence
cdr
indicated
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021528872A
Other languages
English (en)
Japanese (ja)
Other versions
JP7562528B2 (ja
JP2022515318A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2019/126495 external-priority patent/WO2020135201A1/zh
Publication of JP2022515318A publication Critical patent/JP2022515318A/ja
Publication of JP2022515318A5 publication Critical patent/JP2022515318A5/ja
Application granted granted Critical
Publication of JP7562528B2 publication Critical patent/JP7562528B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021528872A 2018-12-28 2019-12-19 抗体及びその用途 Active JP7562528B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201811617535.8 2018-12-28
CN201811617535 2018-12-28
PCT/CN2019/126495 WO2020135201A1 (zh) 2018-12-28 2019-12-19 一种抗体及其用途

Publications (3)

Publication Number Publication Date
JP2022515318A JP2022515318A (ja) 2022-02-18
JP2022515318A5 true JP2022515318A5 (enExample) 2023-07-28
JP7562528B2 JP7562528B2 (ja) 2024-10-07

Family

ID=71126071

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021528872A Active JP7562528B2 (ja) 2018-12-28 2019-12-19 抗体及びその用途

Country Status (6)

Country Link
US (2) US12297265B2 (enExample)
EP (1) EP3904386A4 (enExample)
JP (1) JP7562528B2 (enExample)
KR (1) KR20210109520A (enExample)
CN (2) CN119350498A (enExample)
WO (1) WO2020135201A1 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210109520A (ko) 2018-12-28 2021-09-06 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 항체 및 이의 용도
JP7840511B2 (ja) 2019-02-01 2026-04-06 石▲薬▼集▲団▼巨石生物制▲薬▼有限公司 抗クローディン１８抗体及びそれらの使用の方法
CR20220580A (es) * 2020-05-15 2023-04-11 Sichuan Kelun Biotech Biopharmaceutical Co Ltd Conjugado anticuerpo-fármaco, método de preparación del mismo y uso del mismo
CN113754780A (zh) * 2020-06-04 2021-12-07 四川科伦博泰生物医药股份有限公司 靶向cldn18.2的嵌合抗原受体、其组合物及用途
CN111704669B (zh) * 2020-07-13 2022-05-13 北京凯因科技股份有限公司 一种用于治疗晚期胃癌的抗cldn18全人源化抗体
WO2022063272A1 (en) * 2020-09-28 2022-03-31 Elpiscience (Suzhou) Biopharma, Ltd. Novel anti-claudin18 antibodies
CN114437221B (zh) * 2020-11-05 2023-08-01 北京天广实生物技术股份有限公司 一种癌症检测抗体及其用途
WO2022122709A1 (en) 2020-12-07 2022-06-16 Sotio Biotech A.S. Antibody-drug conjugates based on humanized cldn18.2 antibodies
CN114617961B (zh) * 2020-12-10 2022-12-02 北京东方百泰生物科技股份有限公司 一种抗lag-3单克隆抗体的注射制剂
KR20230124037A (ko) 2020-12-23 2023-08-24 소티오 바이오테크 에이.에스. 종양 특이적 claudin 18.2 항체-약물 접합체
CN115109154A (zh) * 2021-03-17 2022-09-27 三优生物医药(上海)有限公司 一种靶向cldn18.2的抗体或其抗原结合片段及其应用
EP4335873A4 (en) * 2021-05-08 2025-03-19 RemeGen Co., Ltd. ANTI-CLAUDIN 18.2 ANTIBODY AND ANTIBODY-DRUG CONJUGATE THEREOF
CN115611983A (zh) * 2021-07-14 2023-01-17 三优生物医药(上海)有限公司 Cldn18.2结合分子及其用途
CN113801231B (zh) * 2021-08-20 2022-09-02 四川大学华西医院 抗dog-1抗体或其抗原结合片段及其用途
CN113687085A (zh) * 2021-08-27 2021-11-23 复旦大学附属中山医院 一种评估实体肿瘤Claudin18.2蛋白表达的方法和应用
CN115991784A (zh) * 2021-10-19 2023-04-21 宝船生物医药科技(上海)有限公司 抗cd47-cldn18.2双特异性抗体及其用途
CN118139876A (zh) * 2021-10-19 2024-06-04 博奥信生物技术（南京）有限公司 结合cldn18.2的抗体及其用途
AU2022416272A1 (en) * 2021-12-17 2024-07-18 Fortvita Biologics (Singapore) Pte. Ltd. Antibody-drug conjugate targeting claudin18.2
KR102809807B1 (ko) * 2021-12-21 2025-05-16 한림대학교 산학협력단 항-cldn18.2를 포함하는 키메릭 항원 수용체를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 및 이의 제조 방법
CN117229398A (zh) * 2022-06-15 2023-12-15 中山康方生物医药有限公司 抗cldn18.2抗体、其药物组合物及用途
CN116284387B (zh) * 2022-07-15 2025-10-03 台州恩泽医疗中心(集团) 一种抗hla-g2及hla-g6分子的单克隆抗体及用途
EP4558518A2 (en) * 2022-07-22 2025-05-28 The Government of The United States, as represented by The Secretary of The Army Monoclonal antibodies that interfere with iron uptake
CN117777288A (zh) * 2022-09-29 2024-03-29 南京博望医药科技有限公司 抗密蛋白18.2的抗体
WO2024074145A1 (zh) * 2022-10-08 2024-04-11 盛禾(中国)生物制药有限公司 一种结合baffr和cd3的双特异性抗体及其应用
CN117567619A (zh) * 2022-12-13 2024-02-20 华润生物医药有限公司 抗cd73抗体及其用途
CN115947851B (zh) * 2022-12-19 2024-02-13 华润生物医药有限公司 结合cldn18.2的抗体及其用途
EP4653017A1 (en) 2023-01-18 2025-11-26 Tyligand Bioscience (Shanghai) Limited Antibody-drug conjugate and use thereof
CN116813782B (zh) * 2023-08-10 2024-01-23 北京百普赛斯生物科技股份有限公司 一种Claudin-18.2特异性抗体及其应用
CN121969385A (zh) 2023-09-11 2026-05-01 丹娜-法伯癌症研究院 含有il-2变体以增强car t细胞的功能性的car-衔接子
CN117106081B (zh) * 2023-09-28 2024-05-07 北京凯祥弘康生物科技有限公司 一种抗nfl蛋白的捕获抗体
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025078686A1 (en) 2023-10-12 2025-04-17 Sotio Biotech A.S. Combination therapy involving antibody-drug conjugates against claudin18.2 and pd1/pd-l axis inhibitors for treatment of cancer
CN117736329B (zh) * 2023-12-25 2024-11-12 华润生物医药有限公司 抗pd-1抗体及其用途
WO2025148868A1 (zh) 2024-01-08 2025-07-17 泰励生物科技（上海）有限公司 一种抗体偶联药物及其用途
CN118184782A (zh) * 2024-03-13 2024-06-14 河北森朗生物科技有限公司 抗cldn18.2的纳米抗体、嵌合抗原受体及其应用
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2026157729A1 (zh) * 2025-01-24 2026-07-30 广东东阳光药业股份有限公司 抗4-1bb抗体及其应用
WO2026158588A1 (zh) * 2025-01-26 2026-07-30 北京艺妙神州生物医药股份有限公司 抗Claudin18.2的抗体及其应用
CN121673410A (zh) * 2025-11-17 2026-03-17 中国科学院生物物理研究所 基于抗flt3抗体的树突状细胞靶向疫苗及其应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6051228A (en) * 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
EP1997832A1 (en) 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
US9056092B2 (en) 2011-12-02 2015-06-16 Ethicon, Inc. Hemostatic bioabsorbable device with polyethylene glycol binder
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
WO2013174404A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2013174403A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014075697A1 (en) * 2012-11-13 2014-05-22 Biontech Ag Agents for treatment of claudin expressing cancer diseases
IL282953B2 (en) 2012-11-13 2026-02-01 Tron Translationale Onkologie An Der Johannes Gutenberg Univ Mainz Gemeinnutzige Gmbh Agents for the treatment of claudin-expressing cancers
WO2014146672A1 (en) * 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
KR102236367B1 (ko) 2013-07-26 2021-04-05 삼성전자주식회사 DARPin을 포함하는 이중 특이 키메라 단백질
WO2015141862A1 (en) 2014-03-17 2015-09-24 Mitsubishi Tanabe Pharma Corporation Antibody-fynomer conjugates
WO2016165762A1 (en) * 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Drug conjugates comprising antibodies against claudin 18.2
WO2017059900A1 (en) * 2015-10-07 2017-04-13 Biontech Cell & Gene Therapies Gmbh Antigen receptors and uses thereof
WO2018006882A1 (zh) * 2016-07-08 2018-01-11 科济生物医药（上海）有限公司 抗密蛋白18a2的抗体及其应用
WO2018054484A1 (en) * 2016-09-23 2018-03-29 Biontech Ag Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases
CN119219654A (zh) 2017-12-15 2024-12-31 四川科伦博泰生物医药股份有限公司 生物活性物偶联物及其制备方法和用途
CN111447939B (zh) 2018-01-30 2024-07-12 四川科伦博泰生物医药股份有限公司 制备偶联物的方法
CN111542324B (zh) 2018-02-11 2023-09-12 四川科伦博泰生物医药股份有限公司 细胞毒性剂及其偶联物、其制备方法及用途
CA3087423A1 (en) 2018-03-14 2019-09-19 Beijing Xuanyi Pharmasciences Co., Ltd. Anti-claudin 18.2 antibodies
CN116178554B (zh) 2018-05-18 2025-09-09 礼新医药科技(上海)有限公司 抗密蛋白18.2抗体及其用途
CN111110862A (zh) 2018-11-01 2020-05-08 上海健信生物医药科技有限公司 抗cldn18．2抗体的药物偶联体及其制备方法和用途
EP3808376A4 (en) * 2018-06-17 2021-09-01 L&L Biopharma Co., Ltd. CLDN18.2 ANTIBODY, BISPECIFIC ANTIBODY, ADC AND CAR, AND APPLICATIONS THEREOF
WO2020023679A1 (en) 2018-07-25 2020-01-30 Accurus Biosciences, Inc. Novel cldn 18.2-specific monoclonal antibodies and methods of use thereof
US20210380680A1 (en) 2018-12-07 2021-12-09 ZLlP HOLDING LIMITED Anti-claudin antibodies and uses thereof
KR20210109520A (ko) 2018-12-28 2021-09-06 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 항체 및 이의 용도

Similar Documents

Publication Publication Date Title
JP2020510422A5 (enExample)
JP2021531764A5 (enExample)
JP2023539501A5 (enExample)
JP2022526764A5 (enExample)
JP2020501531A5 (enExample)
CN115551889A (zh) 抗cd73抗体及其用途
JP2019523630A5 (enExample)
RU2017145150A (ru) Антитело против pdl-1, его фармацевтическая композиция и применение
JP2022515318A (ja) 抗体及びその用途
JP2018523493A5 (enExample)
RU2016125551A (ru) Биспецифические антигенсвязывающие конструкции против her2
RU2018106452A (ru) Поливалетные и полиспецифичные gitr-связывающие слитые белки
JP2025503322A5 (enExample)
CN117946278A (zh) 多特异性抗体及其制备和使用方法
JP2022550243A5 (enExample)
JP2021534784A5 (enExample)
JP2021520201A5 (enExample)
JP2022512891A5 (enExample)
JP2020502233A5 (enExample)
JP2022551603A5 (enExample)
JP2024504124A5 (enExample)
JP2024538669A5 (enExample)
WO2023060277A1 (en) Composition of multispecific antibodies targeting cdh17-expressing tumors and method of making and using thereof
JP2024515560A5 (enExample)
JP2025503229A5 (enExample)